uu.seUppsala universitets publikasjoner
Endre søk
RefereraExporteraLink to record
Permanent link

Direct link
Referera
Referensformat
  • apa
  • ieee
  • modern-language-association
  • vancouver
  • Annet format
Fler format
Språk
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Annet språk
Fler språk
Utmatningsformat
  • html
  • text
  • asciidoc
  • rtf
Diabetes and CVD risk during angiotensin-converting enzyme inhibitor or angiotensin II receptor blocker treatment in hypertension: a study of 15 990 patients
Uppsala universitet, Medicinska och farmaceutiska vetenskapsområdet, Medicinska fakulteten, Institutionen för folkhälso- och vårdvetenskap, Allmänmedicin och preventivmedicin.
Vise andre og tillknytning
2014 (engelsk)Inngår i: Journal of Human Hypertension, ISSN 0950-9240, E-ISSN 1476-5527, Vol. 28, nr 11, s. 663-669Artikkel i tidsskrift (Fagfellevurdert) Published
Abstract [en]

Differences in clinical effectiveness between angiotensin-converting enzyme inhibitors (ACEis) and angiotensin receptor blockers (ARBs) in the primary treatment of hypertension are unknown. The aim of this retrospective cohort study was to assess the prevention of type 2 diabetes and cardiovascular disease (CVD) in patients treated with ARBs or ACEis. Patients initiated on enalapril or candesartan treatment in 71 Swedish primary care centers between 1999 and 2007 were included. Medical records data were extracted and linked with nationwide hospital discharge and cause of death registers. The 11 725 patients initiated on enalapril and 4265 on candesartan had similar baseline characteristics. During a mean follow-up of 1.84 years, 36 482 patient-years, the risk of new diabetes onset was lower in the candesartan group (hazard ratio (HR) 0.81, 95% confidence interval (CI) 0.69-0.96, P = 0.01) compared with the enalapril group. No difference between the groups was observed in CVD risk (HR 0.99, 95% CI 0.87-1.13, P = 0.86). More patients discontinued treatment in the enalapril group (38.1%) vs the candesartan group (27.2%). In a clinical setting, patients initiated on candesartan treatment had a lower risk of new-onset type 2 diabetes and lower rates of drug discontinuation compared with patients initiated on enalapril. No differences in CVD risk were observed.

sted, utgiver, år, opplag, sider
2014. Vol. 28, nr 11, s. 663-669
HSV kategori
Identifikatorer
URN: urn:nbn:se:uu:diva-237289DOI: 10.1038/jhh.2014.43ISI: 000343661500003PubMedID: 25211055OAI: oai:DiVA.org:uu-237289DiVA, id: diva2:768356
Tilgjengelig fra: 2014-12-03 Laget: 2014-12-01 Sist oppdatert: 2017-12-05bibliografisk kontrollert

Open Access i DiVA

fulltext(649 kB)117 nedlastinger
Filinformasjon
Fil FULLTEXT01.pdfFilstørrelse 649 kBChecksum SHA-512
7d75f194e97ebce6e57bcd2abf75fd80dcc17d1265275bc0062d026b7c52b8e6a680170f44b3b150bb546b889e85db27d81e1e95a6bede5816a646c861d92dbd
Type fulltextMimetype application/pdf

Andre lenker

Forlagets fulltekstPubMed

Personposter BETA

Stålhammar, JanSundström, Johan

Søk i DiVA

Av forfatter/redaktør
Stålhammar, JanSundström, Johan
Av organisasjonen
I samme tidsskrift
Journal of Human Hypertension

Søk utenfor DiVA

GoogleGoogle Scholar
Totalt: 117 nedlastinger
Antall nedlastinger er summen av alle nedlastinger av alle fulltekster. Det kan for eksempel være tidligere versjoner som er ikke lenger tilgjengelige

doi
pubmed
urn-nbn

Altmetric

doi
pubmed
urn-nbn
Totalt: 518 treff
RefereraExporteraLink to record
Permanent link

Direct link
Referera
Referensformat
  • apa
  • ieee
  • modern-language-association
  • vancouver
  • Annet format
Fler format
Språk
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Annet språk
Fler språk
Utmatningsformat
  • html
  • text
  • asciidoc
  • rtf